Artegraft Inc. announces that a three-year prospective, randomized clinical study published in the June 2011 issue of the Journal of Vascular Surgery shows that Artegraft Bovine Carotid Artery (BCA) vascular grafts have a higher patency rate than cuffed ePTFE grafts for hemodialysis who are not eligible for native arteriovenous fistulas.

Conducted at Massachusetts General Hospital, the study concluded that the BCA graft had significantly higher primary and assisted patency rates than the ePTFE graft, making Artegraft an excellent option for patients on hemodialysis who are not eligible for native arteriovenous fistulas.

The study results concluded that the Overall Primary Patency Rate at one year was 60% for Artegraft and 10% for ePTFE. For Assisted Primary Patency Rate at one year, Artegraft was 60% and ePTFE was 20% according to the study results. After two years, the Assisted Primary Rate was 40% for Artegraft and 14% for ePTFE. Study results also concluded that there were less thrombosis and fewer interventions with the Artegraft BCA, as well as no pseudoaneurysms.